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Abstract
Background Malnutrition is a frequent complication in
patients with cancer and can negatively affect the outcome
of treatments. On the other hand, side effects of anticancer
therapies can also lead to inadequate nutrient intake and
subsequent malnutrition. The nutritional screening aims to
identify patients at risk of malnutrition for prompt treatment
and/or careful follow-up.
Methods and results This manuscript highlights the need of
an interdisciplinary approach (oncologist, nutritionist, die-
titian, psychologist, etc.) to empower patients who are
experiencing loss of physiological and biological function,
fatigue, malnutrition, psychological distress, etc., as a result
of cancer disease or its treatment, and maintain an
acceptable quality of life.
Conclusions It is necessary to make all healthcare profes-
sionals aware of the opportunity to identify cancer patients
at risk of malnutrition early in order to plan the best
possible intervention and follow-up during cancer treatment
and progression.
Keywords Nutritional screening.Malnutrition.Cancer
1 Introduction
Cancer is a systemic disease that directly affects the region
of onset and can metastasize to other sites, causing a variety
of complications and loss of progressive organ function.
The development of the disease may be initially slow or
rapidly evolving, unavoidably affecting nutritional status
[1].
Malnutrition is a possible complication in patients with
cancer and can be the first symptom to reveal the presence
of the disease. Even before starting anticancer treatment,
patients can experience profound metabolic and physiolog-
ical alterations with increased needs of macro- and micro-
nutrients [2]. Data on the prevalence of malnutrition vary
broadly depending on the evaluation criteria such as tumor
type, site, and extension, as well as anticancer treatment.
The prevalence of malnutrition among cancer patients has
been estimated to range between 15% and 80% [3]; the
main symptoms embrace weight loss and asthenia of
different degrees. Malnutrition can negatively affect the
clinical decision to resect the tumor, which is the main and
potentially curative step in the management of cancer.
Indeed, malnutrition can increase the incidence of postop-
erative complications, such as delayed wound healing,
dehiscence of anastomosis, morbidity, and mortality [4].
Medical treatment of cancer patients usually focuses on
the administration of cytotoxic agents and/or radiation
therapy. These tools can potentially eradicate or reduce
tumor size, but may have several toxic side effects that in
turn can also weaken the patient, particularly by decreasing
appetite or inducing nausea and vomiting, fatigue, and
asthenia. When malnutrition establishes, it can be necessary
to reduce the dose of cytotoxic agents and/or modify the
radiation timing between temporary or definite cessation of
treatment. Direct associations have been reported between
the necessity to stop or delay anticancer treatment and a
reduction in the time of remission, in overall survival and in
global response rates to radio/chemotherapy [5]. In addi-
tion, malnutrition is an independent risk factor for quality
of life. Malnutrition impairs the immune status and reduces
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of these possible complications, malnutrition represents a
poor prognostic factor and, as such, should be prevented or
detected as early as possible [7].
There are limited data in the literature on the effective-
ness of nutritional screening and early treatment of
malnutrition [8, 9]. An interdisciplinary approach (oncolo-
gist, nutritionist, nurse, dietitian, physical therapist, psy-
chologist, etc.) is necessary for patients who are
experiencing loss of physiological or biological function,
fatigue, malnutrition, psychological distress, and other
symptoms as a result of cancer disease or its treatment.
The aim of such an approach is to improve their quality of
life. Our manuscript aims to enhance attention of profes-
sional healthcare providers and to encourage further studies
into this topic.
2 Etiology of malnutrition
Weight loss in cancer patients is due to diverse factors,
among them the production of inflammatory and catabolic
mediators playing important roles. Such markers include
acute-phase proteins, interleukin-6 (IL-6), or the ubiqui-
tine–proteasome complex whose activity may be increased
by the neoplasm itself, particularly in some rapidly growing
tumors such as those of the pancreas or the lungs [10]. The
neoplastic mass can represent a possible mechanical
obstruction to the way in the digestive tract, causing
dysphagia and impaired swallowing (head-neck, esophageal
cancer, or mediastinic masses), early satiety, nausea,
vomiting (gastric and small bowel tumors), abdominal pain
for intestinal sub-occlusion or occlusion (small and large
bowel, peritoneal carcinomatosis). Moreover, the tumor can
interfere with organ function, for example, causing diarrhea
(pancreatic and biliary cancer) as a result of the lack of
digestive enzymes [1, 11, 12]. The presence of continuous
or occasional pain during eating and digestion may
represent another important factor limiting, quantitatively
and qualitatively, oral intake [6, 13].
Furthermore, following surgery for cancer removal,
gastrointestinal changes can affect the digestive processes
causing, for example, early satiety, dumping syndrome
(gastric surgery), or diarrhea (pancreatic and colonic
resection). Each condition requires specific dietetic inter-
ventions aimed at progressive nutritional rehabilitation.
Finally, anticancer treatments (chemotherapy and radiation
therapy) can cause anorexia, early satiety, nausea, vomiting,
oral and intestinal mucositis with dysphagia, diarrhea,
hemorroids, anal fissures, and modifications in smell and
taste senses. All these symptoms may affect food choices
and contribute to inadequate meal intake and reduced
quality of life [1, 8]. In some cases, co-administered
medications, taken to control symptoms or to treat adverse
effects associated with anticancer treatments, can produce
their own adverse events [6].
2.1 Interaction between malnutrition and therapy
The nutritional and inflammatory status appears to be
correlated with an increased risk of severe hematological
toxicity following anticancer chemotherapy [14]. Moreover,
chemotherapy-induced DNA damage might become more
severe in normal tissues in the presence of alterations of the
cellular immune response due to high protein catabolism
and stimulation of the acute-phase response [15]. Malnu-
trition can influence the outcome of chemotherapy, radia-
tion, and surgery for cancer due to changes in metabolism,
pharmacokinetics, and healing dynamics. Moreover, mal-
nutrition could be responsible for alterations in absorption,
protein binding, hepatic metabolism, and renal elimination
of drugs and their metabolites [15, 16]. In malnourished
patients, a reduced concentration of plasma proteins may
significantly increase the likelihood of toxicity by agents
with high protein binding, such as prednisolone, etoposide,
cisplatinum, paclitaxel, and irinotecan metabolites [15].
Malnutrition decreases the oxidative metabolism in the
liver performed by cytochrome P-450 isoenzymes through
a depletion of nicotinamide adenine dinucleotide phosphate
reserves. Other liver metabolic pathways can also be
impaired, decreasing clearance and thus prolonging drug
half-life. This may lead to greater drug exposure, which
may influence toxicity [15]. The effect of malnutrition on
renal function is less clear, but measurements of inulin
clearance in malnourished children showed a reduced
glomerular filtration rate [16].
2.2 Quality of life
The various complications caused by cancer can affect
patients’ quality of life in many domains: physical (pain,
sleep disturbances, loss of appetite, fatigue, activities of
daily living), social, psychological (depression, anxiety),
and work-related [17, 18]. Depression is a known factor in
the pathophysiology of anorexia and other nutritional
troubles [19]. Together with the nutritional intervention, a
full and appropriate assessment of the patient’s needs must
be performed. A baseline assessment also highlights current
physical and emotional problems that the patient may be
experiencing [17, 18].
3 Malnutrition and cachexia
Malnutrition is a clinical condition of imbalance of energy,
protein, and other nutrients which causes measurable
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clinical outcome [20, 21]. Anorexia and reduced food
intake are frequently neglected in patients with cancer
and contribute to nutritional impairment. Malnutrition, if
not properly and early treated, unavoidably progresses
to cachexia [22]. Not all malnourished patients are
cachectic, but all cachectic patients are invariably mal-
nourished [20].
Cachexia is a multifactorial syndrome characterized by
severe body weight, fat and muscle loss, and increased
protein catabolism due to underlying disease(s) as cancer,
AIDS, chronic obstructive lung disease, and congestive
heart failure. It results from a complex interplay between
underlying disease, disease-related metabolic alterations,
and reduced availability of nutrients (reduced intake,
impaired absorption, and/or increased losses). Once estab-
lished, cachexia cannot be reversed, neither nutritionally
nor with other treatments, and increases patients’ morbidity
and mortality. Contributory factors to the onset of cachexia
are anorexia and metabolic alterations, i.e., inflammatory
status, increased muscle proteolysis, impaired carbohydrate,
and protein and lipid metabolism [20].
Inflammation plays a pivotal role in the pathogenesis of
cachexia: an imbalance between pro-inflammatory (e.g.,
tumor necrosis factor-α [TNF-α], IL-1, IL-6, interferon-γ
[IFN-γ]) and anti-inflammatory (e.g., IL-4, IL-12, IL-15)
cytokines is currently considered to contribute to cachexia
development and progression [23]. Pre-cachexia immedi-
ately precedes cachexia and can be diagnosed in the
presence of all the following criteria: (a) underlying chronic
disease; (b) unintentional weight loss >=5% of usual body
weight during the last 6 months; (c) chronic or recurrent
systemic inflammatory response; and (d) anorexia or
anorexia-related symptoms.
Progressive loss of skeletal muscle mass is the most
clinically relevant phenotypic feature of cachexia and
causes negative clinical consequences on muscle strength,
respiratory function, functional status, and quality of life
[24]. Muscle loss, with increased muscle protein degrada-
tion results from an imbalance between anabolic and
catabolic rates. Systemic inflammation is one of the main
actors together with tumor-derived factors such as
proteolysis-inducing factor, bed rest, and inadequate nutri-
ent intake [24, 25].
4 Nutritional screening and nutritional assessment
Nutritional screening aims to identify patients at risk of
malnutrition in a simple and non-invasive way. A full
evaluation (nutritional assessment) to confirm and classify
the degree of malnutrition will follow. These two steps
allow to early identify and treat patients with malnutrition
or periodically follow-up those at high nutritional risk, to
face any nutritional challenges before significant weight
loss or before other clinical/biological signs of malnutrition
appear [26, 27].
Due to time restrictions by healthcare professionals,
practical organization and costs, nutritional screening
has necessarily to be feasible, speedy, inexpensive, and
non-invasive.
Several more or less complex criteria have been
proposed for nutritional assessment. The full evaluation of
the patients should include data collection about:
1. Social demography (gender, age, professional status,
and living conditions)
2. Primary tumor (site, disease stage at diagnosis) and the
management of the disease (previous and on-going
treatments)
3. Anthropometry (actual weight, body mass index [BMI,
the weight in kilograms divided by the height in
centimeters squared], usual healthy body weight,
unintentional weight loss since the start of the illness,
or appearance of the first symptoms; weight loss during
the last week, the last month, and over the last
6 months;
4. Clinical examination, Subjective Global Assessment
[28] and Karnofsky Index (evaluating functional ca-
pacity) [29];
5. Biochemical data: serum albumin, prealbumin, total
lymphocyte count cholesterol, C reactive protein
(CRP), pseudocholinesterase (PChE) [30–32].
Careful clinical history record and meticulous symptom
assessment are the first steps to become sympathetic with
the patient and to understand his/her conditions in more
detail. Another major step is the compilation, with the help
of a dietitian, of a detailed food record in the days between
chemotherapy cycles (when patients are feeling better) and
the days of treatment; the compilation of questionnaires
about patients’ daily activities (ability to work, social life,
autonomy in personal hygiene, time spent in bed) should
also be recommended [33].
A nutritional screening should be performed at the time
of the diagnosis, possibly before starting the specific
anticancer treatments. Therefore, for patients at risk of
malnutrition, the clinical nutritionist evaluates the patient’s
conditions and jointly with the dietitian, gives strategic
advices on dietary intakes and choices, according to the
scheduled treatment. If the patient is already malnourished
or at high risk of malnutrition, a nutritional support should
be promptly prescribed [34]. Independent of whether
patient is or is not malnourished, periodical follow-up
should be established and timed on the schedules of the
oncologic therapies; an appropriate follow-up should be
performed every 2 or 3 weeks [30–34].
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BMI alone is not a sensitive parameter to analyze
nutritional status because it may still yield high or normal
results in patients with ascites or edema. Unintentional
weight loss could instead be the best single parameter for
detecting malnutrition [30, 35]. Serum albumin level is the
most widely used clinical nutritional index, but for its
relatively long half-life and correlation with stress and
illness, it remains a non-specific parameter of nutritional
status. Indeed, pro-inflammatory tumor-derived mecha-
nisms influence the acute-phase protein response in the
liver and thus albumin synthesis. Acute-phase reactants
comprise a range of proteins that rapidly change in plasma
concentration responding to inflammation or tissue injury
[36].
“Positive” acute-phase proteins, such as CRP, directly
rise with inflammatory disease activity. “Negative” acute-
phase proteins (albumin, prealbumin, and transferrin)
respond inversely: their levels decrease in response to
injury and inflammation and increase during recovery from
the same conditions. Decreased serum levels of albumin,
prealbumin, and transferrin do not necessarily reflect a state
of malnutrition, but could be a consequence of the body’s
physiologic response to injury. Under these conditions,
resolution of inflammation, and not exogenous substrate
(protein and energy) from nutritional support, restores
normal hepatic protein metabolism and, eventually, serum
levels of negative acute-phase proteins [36].
Recently, the role of plasma PChE as nutritional index
has been described: its levels were found to be decreased in
malnourished patients with or without hepatic involvement
[37]. One of the possible mechanisms responsible for PChE
activity reduction in cancer patients could be anorexia,
which accompanies malignancy, as happens in anorexia
nervosa too [38]. Bozzetti et al. observed that PChE, body
weight, and nitrogen balance improved during nutritional
support in cancer patients [39]. To adequately assess
nutritional status in patients with cancer and in order to
avoid possible interferences by inflammation and tumor-
derived factors, not a single parameter but a cluster of two
or more parameters should be considered [12, 35].
5 Treatment of malnutrition
5.1 Nutritional intervention and supplement
Research in clinical oncology has focused mainly on
defining the best practice to evaluate anticancer treatment—
cytotoxic drugs, radiation, and surgical procedures—as
well as to clarify the traditional endpoints of disease-free
and overall survival. Malnutrition is associated with
negative outcomes including increased morbidity, poor
prognosis and tolerance to treatment, decreased quality of
life, and increased health care costs [1]. Patients with or at
risk of malnutrition should receive the most appropriate
nutritional support (oral supplements or enteral/parenteral
support; Fig. 1). Furthermore, such patients should be
followed-up during the evolution of the disease. For each
single patient, for the specific type of cancer and for the
involved body areas, all variables that could negatively
affect the nutritional status should be identified and treated
according to appropriate protocols and decisional algo-
rithms [32].
The nutritional support has to be personalized according
to the nutritional status of the single patient, to the toxicity
of the respective patient’s therapy, and to the influence of
symptoms on the daily eating requirements. For example, in
case of nausea and vomiting in the 5–7 days following
chemotherapy with strong impairment of eating in already
malnourished patients, parenteral nutritional support can be
considered. Under the same conditions, for a well-
nourished patient, a hydrating–detoxifying therapy could
be appropriate [34, 37].
Head/neck cancer patients generally experience a con-
siderable weight loss and malnutrition for dysphagia,
mucositis, and xerostomy during and following radiation
therapy. Reported risk factors associated with serious
weight loss are: baseline Karnofsky performance status less
than 80, combination with chemotherapy, and receiving a
total dose of radiation of 60 Gray or more [29]. Treatment
toxicity may be exacerbated by poor nutritional status
before and during therapy and may impair recovery time
because of the effects of malnutrition on wound healing.
Malnutrition may compromise treatment efficacy and
reduce quality of life, possibly even affect survival [4, 7].
In patients with head/neck cancer on radiotherapy or
combined chemo- and radiotherapy, weight loss generally
commences in the second week of therapy. Considering that
the gastrointestinal tract distal of the tumor and the treatment
field is usually functional, enteral rather than parenteral
feeding yields safer and more physiological results. The
positioning of a nasogastric tube (NGT) for enteral nutrition
can be advisable when a temporary dysphagia is anticipated
(during and soon after radiation therapy). On the other hand,
at stage 3 or 4 of the disease, the prophylactic placement of a
percutaneous gastrostomy (PEG) for early enteral nutrition
can be a reasonable approach [40].
While NGT positioning has generally been recommen-
ded when nutritional support is required for a short period
of time (less than 1 month), PEG tubes are the better choice
for prolonged nutritional support [41].
In malnourished patients who undergo radiotherapy as
single or concomitant therapy for gastrointestinal neo-
plasms, abdominal pain, nausea, vomiting, or diarrhea
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absorption. Therefore, a parenteral nutritional therapy
through peripheral veins or preferably through a pre-
existing central venous catheter could be necessary [42].
In patients requiring abdominal radiation, enteritis may
develop, causing malabsorption and/or obstruction due to
intestinal fibrosis or stenosis. These patients need specific
dietary recommendations, such as semiliquid, hyperproteic,
fiber-free, or lactose-free diet [43, 44].
Adequate education regarding the prevention and treat-
ment of diarrhea and constipation is also important. Dietary
supplements and alternative foods have to be discussed and
prescribed [45, 46]. Also, patients with a regular oral intake
need to be followed-up closely to prevent or diagnose and
treat malnutrition as early as possible.
During inflammatory processes, tissue depletion results
in protein and fat loss as a result of the actions of pro-
inflammatory cytokines. Besides the inflammatory condi-
tion of cancer, chemotherapy increases oxidative stress,
thereby providing a further boost to the inflammatory
process. Hypercaloric/hyperproteic oral supplements could
be indicated, due to the hypercatabolism induced by the
tumor and chemotherapy [47, 48].
Many formulas are now disposable, with high or low fat
content, enriched with anti-inflammatory and antioxidant
agents. Among nutrients acting on the inflammatory
process are n-3-polyunsaturated fatty acids (n-3-PUFA)
and antioxidants. Eicosapentaenoic acid (EPA) is an n-3,
21-carbon atom, polyunsaturated fatty acid, with five
double bonds, found in oily fish. It seems to attenuate
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
DIAGNOSIS OF 
CANCER
Nutritional counseling 
Presence of malnutrition 
Absence of malnutrition 
Periodical nutritional evaluation at 
established intervals  Evaluate the most appropriate 
nutritional supplementation 
Is the gastrointestinal tract functioning? 
(exclude the presence of diarrhea, 
subocclusion, nausea, vomiting and abdominal 
pain) 
NO
YES 
Is there or will there be dysphagia 
(swallowing difficulties for 
mucositis,  mechanical obstacles 
or neurological impairment)? 
NO 
YES 
For short to medium term 
nutritional support, and frail 
peripheral veins: evaluate 
the opportunity of  
positioning a PICC or a 
midline catheter. 
Infusion therapy aiming to  
hydrate and detoxify or 
parenteral nutrition
Are peripheral veins 
suitable?
Oral supplements, 
procinetics and/or 
appetite stimulants 
Evaluate the opportunity of  a 
nasogastric tube (short-term EN) or 
gastrostomy (long-term EN) 
positioning  
What will be the duration of the 
cytotoxic intravenous treatment?
NO 
YES
For short-term 
nutritional/infusion support 
and suitable veins: 
Peripheral parenteral 
nutrition/hydration may be 
indicated
Short duration 
(es: adjuvant 
therapy Medium/long 
duration
For long-term 
nutritional 
support, evaluate 
the opportunity of 
positioning 
central venous 
access. 
Fig. 1 Algorithm for nutritional
evaluation. PICC: peripherally
inserted central venous catheter.
EN: enteral nutrition
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down-regulating the increased expression and activity of
the ubiquitin–proteasome proteolytic pathway [45, 47, 48].
Since EPA has no effects on protein synthesis in muscle,
EPA has been combined with nutritional supplements rich
in protein and energy, such as branched chain amino acids
[49].
Fearon’s group has pioneered the use of fish oil in the
treatment of pancreatic cancer, reporting the ability of n-3
PUFA, in particular, EPA and docosahexaenoic acid to
reduce weight loss rate in such patients. Glutamine acts as a
source of glutamate and may provide one of the three
amino acids (glycine, cysteine, and glutamate) required for
the synthesis of the key antioxidant glutathione, indirectly
reducing inflammatory stress in the patients [45]. Antiox-
idants represent one of the largest categories of dietary
supplements, which could be protective against the adverse
effects of chemotherapy [49]. Severely malnourished
patients with decreased dietary carnitine uptake may
develop carnitine deficiency when treated with cisplatin, as
the drug increases renal carnitine excretion approximately
tenfold [50].
Trace elements consist mostly of metal ions acting
mainly as basic components of essential enzymatic
systems or proteins, which play major roles in the
physiology of the gastrointestinal tract. Some studies
suggest that trace elements serve as co-factors in several
metabolic pathways and a decrease in their concentration
may facilitate the malnutrition process. Selenium defi-
ciency may interfere with free radical-mediated damage.
Zinc regulates the function of cytochromes, stabilizes
plasma membranes, reduces lipid peroxidation, and has a
role in the detoxification of ammonia. Supplementation
of these trace elements can delay cachexia onset with its
subsequent depression of the immune system, influencing
the neoplastic process and the effect of chemotherapy
[51, 52].
5.2 Agents affecting appetite
Cachexia is strongly associated with anorexia. Besides oral
caloric supplementation, early preventive and treatment
attempts have thus suggested the use of appetite stimulants.
The most widely prescribed is megestrol acetate, a synthetic
progestin, which may stimulate appetite via neuropeptide Y
in the ventromedial hypothalamus and by down-regulating
the synthesis and release of pro-inflammatory cytokines. A
systematic review of 15 randomized clinical trials of high-
dose progestin therapy has showed a statistically significant
improvement in both appetite and body weight. However,
body composition analysis of patients who gained weight
showed that weight gain was due to increased fat and not
lean body mass [53].
Similar results have been obtained with another proges-
tin, medroxyprogesterone acetate [54]. The inability of
these two progestins to increase lean body mass would
explain why patients show no significant improvement in
the Karnovsky Index (performance score) or in quality of
life. Moreover, attention should be paid on the prescription
of progestins for the increased risk of thrombo-embolic
phenomena and edema [55]. Thus, cyproheptadine, a
histamine antagonist with antiserotonergic and appetite-
stimulating effects, produces only a slight improvement in
appetite and does not significantly prevent progressive
weight loss in anorectic cancer patients [56].
Corticosteroids such as dexamethasone, prednisolone,
and methylprednisolone are used to enhance appetite,
sensation of well-being and performance, usually at the
end-stage of cancer, because of their catabolic effect on
skeletal muscle. However, despite possible improvement in
quality of life, they have no other beneficial effects [57].
Several neuropeptides regulate appetite and are currently
under evaluation to assess their efficacy in the treatment of
cancer anorexia/cachexia. Among these is ghrelin, a
neuropeptide released from the stomach in response to
fasting that stimulates food intake. The use of ghrelin has
recently been reviewed elsewhere [58].
5.3 Treatment of mucositis
The cytotoxic effects of chemotherapy and radiation
therapy can cause an inflammatory response of mucosal
epithelial cells called mucositis. All mucous membrane-
covered surfaces, from mouth to rectum, may be affected
[59]. Oral mucositis disrupts the function and integrity of
the oral cavity, affecting a satisfying oral food intake and
negatively influencing treatment outcomes and quality of
life. It is associated with significant clinical morbidity,
which may include pain, dysphagia, malnutrition, and local
and systemic infections.
The largest damage at the oral mucosa is seen in patients
with head/neck cancer treated with a combination of radio-
and chemotherapy. Although present throughout the gas-
trointestinal tract, mucositis in the oral cavity has been
better characterized in the literature because of the ease of
assessment [60]. Oral care is widely considered the basis of
mucosal health, integrity, and function. However, the
specific components, methods, and frequency of this
treatment remain in debate, partly because of the ethical
considerations of withholding oral care in clinical trials
[62].
In physiological conditions, the human saliva has
lubricating properties and antibacterial/antiviral actions;
disturbances of the salivary flow alter the protective role
of oral microflora. Oral care protocols could help to
minimize the effects of oral mucositis in patients receiving
32 J Cachexia Sarcopenia Muscle (2011) 2:27–35treatment for cancer: it can reduce the amount of microbial
flora, control pain and bleeding, and prevent infection.
Good oral health also reduces the risk of gingival and
dental complications [58, 59]. Few data are available on
the use of sodium-bicarbonate rinsing to alkalinize oral
cavity, followed by the prophylactic use of an antiseptic
(chlorexidine-based) and/or antifungine (nystatin, itraco-
nazole) mouth washes. Also doubtful is the benefit of
using local hydrating agents containing jaluronic acid and
other cicatrizing agents.
6 Cancer rehabilitation
The clinical evaluation of patients with cancer has to
include nutritional assessment [1, 28]. Depending on the
needs of the patient and his/her family, members of the
rehabilitation team may include any or all involved
physicians, oncology nurses, dietitians, physiotherapists,
and psychologists. The team has to address the potential
rehabilitation needs of the individual from cancer diagnosis
to rehabilitation, covering the following objectives: pain-
killer therapy, nutritional and psychosocial support, and
optimization of physical and social functioning [2, 8]. The
implementation of a nutritional surveillance could enable
rapid treatment of symptoms (anorexia, dysphagia, nausea,
vomiting, constipation, tiredness, etc.), which could have a
role in the malnutrition process [4]. The first step of cancer
rehabilitation is the primary support to the negative effects
of cancer disease and its therapy [6–8]. Oncologists have to
be encouraged to share their work with other team special-
ists: anesthesiologists for pain therapy, nutritionists for
nutritional support, and physical and rehabilitation medi-
cine specialists. Physiotherapists, dietitians, and specialized
nurses complete the team. All these figures have to
cooperate to symptoms’ management of cancer patients
[32, 33]. It is necessary to achieve early treatment of
malnutrition to avoid a gradual progression to cachexia, an
irreversible condition. Patients have to be treated when an
effective intervention is still possible, before cachexia
manifests. It will be meaningless and unethical to treat the
irreversible phase of cachexia, when the patient is almost at
the end of life [61, 62]. In that condition, hydration is
indicated [63]. Malnutrition and above all cachexia have to
be prevented and/or followed-up from the first diagnosis of
cancer [64].
Evaluating data reported in the literature, it appears that
few patients receive early nutritional counseling and
nutritional issues are often underestimated in the diagnostic
and therapeutic course of cancer rehabilitation [65]. This
seems to be related to excessive workload and insufficient
knowledge/skill among healthcare professionals expected to
take on the task of screening.
7 Conclusions
It is necessary to make all healthcare professionals aware of
the opportunity to screen cancer patients and identify those
at risk of malnutrition. It is a duty of any physician and the
patients’ right to improve preventive actions and intervene
early during cancer treatment and progression of the disease
[4, 6].
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